Protara Therapeutics, Inc. (NASDAQ:TARA) Stock Short Interest Report for October

Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report) saw a significant drop in short interest in the month of October. As of October 30th, there was short interest totaling 3,236,659 shares, a drop of 46.9% from the October 15th total of 6,094,189 shares. Based on an average daily volume of 1,127,185 shares, the short-interest ratio is presently 2.9 days. Currently, 5.9% of the shares of the stock are sold short.

Protara Therapeutics Stock Down 2.5%

Protara Therapeutics stock opened at $2.32 on Wednesday. The stock’s fifty day simple moving average is $2.83 and its 200-day simple moving average is $4.35. Protara Therapeutics has a twelve month low of $2.09 and a twelve month high of $7.82.

Protara Therapeutics (NASDAQ:TARA – Get Free Report) last released its quarterly earnings data on Friday, November 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.02. On average, analysts predict that Protara Therapeutics will post -1.37 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Corient Private Wealth LP purchased a new position in Protara Therapeutics during the second quarter worth $41,000. Squarepoint Ops LLC acquired a new position in Protara Therapeutics in the 2nd quarter valued at about $69,000. The Manufacturers Life Insurance Company lifted its holdings in Protara Therapeutics by 22.2% in the 1st quarter. The Manufacturers Life Insurance Company now owns 13,548 shares of the company’s stock valued at $71,000 after purchasing an additional 2,464 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new position in Protara Therapeutics in the 2nd quarter valued at about $113,000. Finally, WINTON GROUP Ltd boosted its stake in shares of Protara Therapeutics by 16.7% during the 2nd quarter. WINTON GROUP Ltd now owns 32,800 shares of the company’s stock worth $125,000 after purchasing an additional 4,700 shares during the last quarter. 38.13% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Wall Street Zen raised shares of Protara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 5th. Cantor Fitzgerald restated an “overweight” rating on shares of Protara Therapeutics in a research report on Thursday, October 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Thursday, October 15th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $26.25.

Read Our Latest Analysis on TARA

Protara Therapeutics Company Profile

(Get Free Report)

Protara Therapeutics is a clinical-stage biotechnology company developing treatments for cancer and rare diseases. Its programs are investigational and are not approved for general use. The company’s lead program, TARA-002, is a cell-based immunotherapy being studied for non-muscle invasive bladder cancer and lymphatic malformations. Protara is also developing intravenous choline chloride for people with intestinal failure-associated liver disease. Protara was formed in 2019 through a merger involving ArTara Therapeutics.

Featured Stories

Receive News & Ratings for Protara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.